ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback